Papel de los tratamientos de fondo en las artropatías inflamatorias

van der Heide, 1996, The effectiveness of early treatment with «second-line» antirheumatic drugs. A randomized, controlled trial, Ann. Intern. Med., 124, 699, 10.7326/0003-4819-124-8-199604150-00001 Scott, 2000, The links between joint damage and disability in rheumatoid arthritis, Rheumatol., 39, 122, 10.1093/rheumatology/39.2.122 Hulsmans, 2000, The course of radiologic damage during the first six years of rheumatoid arthritis, Arthritis Rheum., 43, 1927, 10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B Strand, 1999, Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate, Arch. Intern. Med., 159, 2542, 10.1001/archinte.159.21.2542 Sharp, 1998, Treatment with leflunomide slows radiographic progression of rheumatoid arthritis, Arthritis Rheum., 43, 495, 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U Situnayake, 1987, Long-term treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine: a comparison using life-table methods, Ann. Rheum. Dis., 46, 177, 10.1136/ard.46.3.177 Chu, 1991, Localization of tumor necrosis factor-α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis, Arthritis Rheum., 34, 1125, 10.1002/art.1780340908 Williams, 1992, Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis, Proc. Natl. Acad. Sci. USA, 89, 9784, 10.1073/pnas.89.20.9784 Elliot, 1993, Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor alpha, Arthritis Rheum., 36, 1681, 10.1002/art.1780361206 Elliott, 1994, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha(cA2) versus placebo in rheumatoid arthritis, Lancet, 344, 1105, 10.1016/S0140-6736(94)90628-9 Elliott, 1994, Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis, Lancet, 344, 1125, 10.1016/S0140-6736(94)90632-7 Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum., 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N. Engl. J. Med., 343, 1594, 10.1056/NEJM200011303432202 Maini, 2004, Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate, Arthritis Rheum., 50, 1051, 10.1002/art.20159 Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N. Engl. J. Med., 348, 601, 10.1056/NEJMoa020888 Moreland, 1996, Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis, J. Rheumatol., 23, 1849 Moreland, 1997, Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, N. Engl. J. Med., 337, 141, 10.1056/NEJM199707173370301 Moreland, 1999, Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial, Ann. Intern. Med., 130, 478, 10.7326/0003-4819-130-6-199903160-00004 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N. Engl. J. Med., 340, 253, 10.1056/NEJM199901283400401 Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised clinical trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 Breedveld, 2004, Infliximab in active early rheumatoid arthritis, Ann. Rheum. Dis., 63, 149, 10.1136/ard.2003.013961 Bathon, 2000, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis, N. Engl. J. Med., 343, 1586, 10.1056/NEJM200011303432201 Genovese, 2002, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes, Arthritis Rheum., 46, 1443, 10.1002/art.10308 Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate, Arthritis Rheum., 48, 35, 10.1002/art.10697 Furst, 2003, Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J. Rheumatol., 30, 2563 Traitements anti-TNF alpha et suivi de la tolérance. Fiches pratiques élaborées par le Club Rhumatismes et Inflammation (CRI). Rev Rhum Mal Ostéoartic 2004;71(hors série n°5). Cohen, 2004, The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis, Rheum. Dis. Clin. North Am., 30, 365, 10.1016/j.rdc.2004.01.005 Dougados, 1995, Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study, Arthritis Rheum, 38, 618, 10.1002/art.1780380507 Marshall, 2001, Methotrexate in the treatment of ankylosing spondylitis: a three-year open study, Clin. Rheumatol., 30, 313 Braun, 2002, Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet, 359, 1187, 10.1016/S0140-6736(02)08215-6 Davis, 2003, Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis, Arthritis Rheum., 48, 3230, 10.1002/art.11325 Mease, 2000, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385, 10.1016/S0140-6736(00)02530-7 Felatar, 2004, Treatment of refractory psoriasic arthritis with infliximab: a 12-month observational study of 16 patients, Ann. Rheum. Dis., 63, 156, 10.1136/ard.2003.006775